FOR RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION.

GLP-2 — Published Research

Reviewed by: Elizabeth D.| Last updated: April 15, 2026|For laboratory reference only

← Back to GLP-2 product page

View Lab Reports · Quality & Testing · FAQ

Research Library

Published research on this compound — for educational purposes only

Mechanism as an imbalanced dual agonist

GLP-2 is characterized as an “imbalanced” dual agonist because it displays full agonism at the GIP receptor but biased agonism at the GLP-1 receptor. At the GLP-1R, GLP-2 preferentially activates Gαs-mediated cAMP signaling while exhibiting reduced β-arrestin recruitment compared to native GLP-1. This biased signaling profile results in less receptor internalization and potentially sustained receptor surface availability. The compound’s C-20 fatty diacid moiety enables albumin binding and alters its stability profile in preclinical characterization. Research compound — not outside laboratory research use.

Willard FS, et al. JCI Insight. 2020;5(17):e140532. JCI Insight

GLP-1R signaling vs selective GLP-1 agonists

Unlike selective GLP-1 receptor agonists such as GLP-1 S, GLP-2 demonstrates biased agonism at GLP-1R characterized by reduced β-arrestin-1 recruitment. Selective GLP-1 agonists activate both cAMP and β-arrestin pathways with relatively balanced efficacy, leading to robust receptor internalization. GLP-2’s biased profile — favoring cAMP over β-arrestin — may alter receptor trafficking dynamics. The simultaneous engagement of GIP receptors with full agonism distinguishes GLP-2’s pharmacological signature from mono-agonist compounds. Research compound — not outside laboratory research use.

Min Q, et al. Proc Natl Acad Sci USA. 2022;119(34):e2116506119. PNAS

cAMP vs β-arrestin receptor pharmacology

In cell-based assays, GLP-2 activates GIP receptor-mediated cAMP accumulation with potency comparable to native GIP. At the GLP-1 receptor, GLP-2 generates cAMP with approximately 5-fold lower potency than native GLP-1, but displays markedly reduced (>100-fold) β-arrestin-1 and β-arrestin-2 recruitment. This dissociation between G-protein signaling and arrestin recruitment defines GLP-2 as a G-protein-biased agonist at GLP-1R. Research compound — not outside laboratory research use.

Willard FS, et al. JCI Insight. 2020;5(17):e140532. JCI Insight

Structural basis for dual receptor engagement

GLP-2 is a 39-amino acid linear peptide based on the native GIP sequence with modifications enabling GLP-1R cross-reactivity. Key structural features include an α-aminoisobutyric acid (Aib) substitution at position 2 conferring DPP-4 resistance, and a C-20 fatty diacid moiety conjugated via a linker at lysine-20 enabling non-covalent albumin binding. The exendin-4-derived C-terminal extension (positions 35-39) contributes to GLP-1R engagement. Research compound — not outside laboratory research use.

Min Q, et al. Proc Natl Acad Sci USA. 2022;119(34):e2116506119. PNAS

Disclaimer: All research citations are provided as references to published laboratory literature only. These materials may summarize in vitro and animal-model findings. Products are sold strictly for laboratory research use. Not outside laboratory research use. No statements on this page are intended as protocol or application guidance.

Reviewed by

Elizabeth D.

Research content reviewer focused on peptide literature review, documentation quality, and reference completeness.

Editorial Review

Reviewed by Elizabeth D. and James S. — Panda Peptides Research Team.

Last reviewed: April 2026.

This content summarizes published laboratory literature for research-reference purposes only. Products referenced by Panda Peptides are sold strictly for laboratory research use. This page is not intended as dosing, administration, treatment, or other human-use guidance.